Novimmune's NI-0501 Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients With Primary Hemophagocytic ...
GENEVA, SWITZERLAND -- (Marketwired) -- 03/16/16 -- Novimmune, a Swiss biotech company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to NI-0501 for the treatment of patients with primary HLH …